Correlation Between Dyadic International and Adaptimmune Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Dyadic International and Adaptimmune Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dyadic International and Adaptimmune Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dyadic International and Adaptimmune Therapeutics Plc, you can compare the effects of market volatilities on Dyadic International and Adaptimmune Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dyadic International with a short position of Adaptimmune Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dyadic International and Adaptimmune Therapeutics.

Diversification Opportunities for Dyadic International and Adaptimmune Therapeutics

0.63
  Correlation Coefficient

Poor diversification

The 3 months correlation between Dyadic and Adaptimmune is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Dyadic International and Adaptimmune Therapeutics Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adaptimmune Therapeutics and Dyadic International is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dyadic International are associated (or correlated) with Adaptimmune Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adaptimmune Therapeutics has no effect on the direction of Dyadic International i.e., Dyadic International and Adaptimmune Therapeutics go up and down completely randomly.

Pair Corralation between Dyadic International and Adaptimmune Therapeutics

Given the investment horizon of 90 days Dyadic International is expected to generate 0.34 times more return on investment than Adaptimmune Therapeutics. However, Dyadic International is 2.95 times less risky than Adaptimmune Therapeutics. It trades about -0.16 of its potential returns per unit of risk. Adaptimmune Therapeutics Plc is currently generating about -0.08 per unit of risk. If you would invest  138.00  in Dyadic International on February 24, 2025 and sell it today you would lose (38.00) from holding Dyadic International or give up 27.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Dyadic International  vs.  Adaptimmune Therapeutics Plc

 Performance 
       Timeline  
Dyadic International 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Dyadic International has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in June 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.
Adaptimmune Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in June 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Dyadic International and Adaptimmune Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Dyadic International and Adaptimmune Therapeutics

The main advantage of trading using opposite Dyadic International and Adaptimmune Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dyadic International position performs unexpectedly, Adaptimmune Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will offset losses from the drop in Adaptimmune Therapeutics' long position.
The idea behind Dyadic International and Adaptimmune Therapeutics Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments